A Multicenter Study with a Randomized, Double-Blind, Comparator-Controlled Induction Dosing Period Followed by a Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 compared to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Trial Profile

A Multicenter Study with a Randomized, Double-Blind, Comparator-Controlled Induction Dosing Period Followed by a Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 compared to Ustekinumab in Patients with Moderate-to-Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2016

At a glance

  • Drugs Ixekizumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2016 Status changed from recruiting to completed.
    • 18 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top